Biotech Values

[jessellivermore]

"guilt by association with AMRN"

Dew perhaps I misunderstand you...Are you suggesting Epanova is a serious competitor to Vascepa??..It is not.. Epanova is just "son of Lovaza".

Vascepa is guilty of nothing but the normal garden variety impatience and ignorance that characterizes the stock market...particularly in the field of biotechs...I know nothing about Vascepa the would cause me the least bit of concern..

The way I see it...all these degenerative conditions where there seems to be some benefit from fish oil represent therapeutic possibilities which have not materialized simply because the dosages of EPA have been too low...Dry-Red eye syndrome is one I am personally familiar with and can say categorically there is no current treatment that can compete with Vascepa...There will be many other conditions that will form a long list as they are related to our diet...

I know you remain a skeptic, but I feel you are missing the boat...

Regards..":>) JL